User profiles for Mahdad Noursadeghi
 | Mahdad NoursadeghiUniversity College London Verified email at ucl.ac.uk Cited by 15948 |
[PDF][PDF] SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses
On 24 th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529
was announced, containing far more mutations in Spike (S) than previously reported …
was announced, containing far more mutations in Spike (S) than previously reported …
Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C …
…, JS Nguyen-Van-Tam, L Norman, M Noursadeghi… - bmj, 2020 - bmj.com
Objective To develop and validate a pragmatic risk score to predict mortality in patients admitted
to hospital with coronavirus disease 2019 (covid-19). Design Prospective observational …
to hospital with coronavirus disease 2019 (covid-19). Design Prospective observational …
Immune boosting by B. 1.1. 529 (Omicron) depends on previous SARS-CoV-2 exposure
…, D Muñoz Sandoval, SM Murray, M Noursadeghi… - Science, 2022 - science.org
The Omicron, or Pango lineage B.1.1.529, variant of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) carries multiple spike mutations with high transmissibility and …
coronavirus 2 (SARS-CoV-2) carries multiple spike mutations with high transmissibility and …
[HTML][HTML] Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2
Individuals with potential exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
do not necessarily develop PCR or antibody positivity, suggesting that some …
do not necessarily develop PCR or antibody positivity, suggesting that some …
Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine rollout has coincided
with the spread of variants of concern. We investigated whether single-dose vaccination, …
with the spread of variants of concern. We investigated whether single-dose vaccination, …
[HTML][HTML] Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study
…, A Torralbo, L Shallcross, M Noursadeghi… - The Lancet, 2020 - thelancet.com
Background The medical, societal, and economic impact of the coronavirus disease 2019 (COVID-19)
pandemic has unknown effects on overall population mortality. Previous models …
pandemic has unknown effects on overall population mortality. Previous models …
[HTML][HTML] Evolution of enhanced innate immune evasion by SARS-CoV-2
…, P Bonfanti, K Shokat, N Jura, K Verba, M Noursadeghi… - Nature, 2022 - nature.com
The emergence of SARS-CoV-2 variants of concern suggests viral adaptation to enhance
human-to-human transmission 1 , 2 . Although much effort has focused on the characterization …
human-to-human transmission 1 , 2 . Although much effort has focused on the characterization …
[HTML][HTML] Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
Most vaccine platforms use a two-dose prime-boost approach to generate an immune
response against the virus S1 spike protein, the titres of which correlate with functional virus …
response against the virus S1 spike protein, the titres of which correlate with functional virus …
[HTML][HTML] Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP …
Background Microbiological characterisation of co-infections and secondary infections in
patients with COVID-19 is lacking, and antimicrobial use is high. We aimed to describe …
patients with COVID-19 is lacking, and antimicrobial use is high. We aimed to describe …
[HTML][HTML] COVID-19: PCR screening of asymptomatic health-care workers at London hospital
…, X Couto-Parada, T Cutino-Moguel, M Noursadeghi… - The Lancet, 2020 - thelancet.com
The exponential growth in coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) across the UK has been successfully …
respiratory syndrome coronavirus 2 (SARS-CoV-2) across the UK has been successfully …